Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy role

As Eli Lil­ly an­tic­i­pates an FDA weight loss ap­proval for its in-de­mand di­a­betes drug Moun­jaro by year’s end, the drug­mak­er’s leader of those two ar­eas will re­tire and be re­placed by its im­munol­o­gy head.

Mike Ma­son, pres­i­dent of Lil­ly Di­a­betes and Obe­si­ty, will de­part at the end of De­cem­ber af­ter a 34-year ca­reer at the In­di­anapo­lis-based Big Phar­ma, per a Wednes­day morn­ing an­nounce­ment. Lil­ly USA pres­i­dent and im­munol­o­gy pres­i­dent Pa­trik Jon­s­son, an­oth­er three-decade vet­er­an of the com­pa­ny, will take Ma­son’s place on Jan. 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER